HOME >> MEDICINE >> NEWS
EVEREST data on use of tolvaptan published in JAMA and featured at ACC

PRINCETON, N.J., March 25, 2007-- Once-daily dosing with Otsuka's investigational oral medication tolvaptan, a vasopressin receptor antagonist, was associated with improvements in signs and symptoms of acutely decompensated heart failure (ADHF) in hospitalized patients receiving conventional care, without an adverse effect on their long-term survival versus placebo. These data are from the short- and long-term analyses of the international landmark trial Efficacy of Vasopressin antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) published in the March 28 issue of the Journal of the American Medical Association (JAMA). These data were presented at the American College of Cardiology's 56th Annual Scientific Sessions (ACC).

The phase 3 EVEREST trial, involving a total of 4,133 ADHF patients, represents three studies: a long-term outcomes trial evaluating patients after their discharge for a minimum of 60 days of treatment, and two identical, embedded short-term pivotal studies that examined tolvaptan compared to placebo over seven days of inpatient care or discharge, whichever came first.

Data from the two short-term studies documented that tolvaptan treatment yielded significantly greater improvements than placebo based on the primary endpoint (study A: p less than 0.001 and study B: p less than 0.001), which was the composite score of changes in patient-assessed global clinical status and changes in body weight at day seven or discharge. Long-term tolvaptan use did not differ from placebo on either of the study's two primary endpoints: deaths from all causes (p equal to 0.68) or from the combined endpoint of cardiovascular (CV) deaths or subsequent hospitalization for worsening HF (p equal to 0.55).

"Tolvaptan exhibited short-term symptomatic benefits in patients hospitalized with worsening heart failure," said investigator Marvin A. Konstam, M.D., chief of the Division of Cardiology at the Tufts- New England
'"/>

Contact: Debra Kaufmann
debra.kaufmann@otsuka.com
240-683-3568
Porter Novelli
27-Mar-2007


Page: 1 2 3 4 5

Related medicine news :

1. Is most published research really false?
2. Bayer and Onyx announce pivotal Nexavar kidney cancer study published in NEJM
3. In stroke, negative studies less likely to get published
4. Landmark study on diabetic foot infection published
5. New international standards for tuberculosis care published
6. Research published in the NEJM challenges 30-year-old standard of care for lupus patients
7. Newly published summer camp health guideline advises parents, camp directors
8. Child sex abuse policy recommendations published in Science magazine
9. Aqueous Humor Outflow featured in Investigative Ophthalmology & Visual Science
10. Health effects of functional foods featured during four-day symposium, Sept. 10-13
11. Rare, historic medical cartoons to be featured in film series

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: EVEREST data use tolvaptan published JAMA and featured ACC

(Date:10/31/2014)... (PRWEB) October 31, 2014 The Memory Healer ... created by Alexander Lynch, whose father suffered from Alzheimer's disease. ... dramatic moment, caused by his father's disease. His father pointed ... was the crucial moment when the author of this method ... dad. , The Memory Healer program is based on ...
(Date:10/31/2014)... With all the preparations families carry out ... may overlook one critical area – the potential for ... performance and even behavior. Typical children’s vision screenings at ... vision problems, and to address this challenge, Dr. Rosenak’s ... The Awesome Eyes Student Vision Program. , The ...
(Date:10/31/2014)... -- Obesity increases the risk of certain types of ... new U.S. studies show. One study of more ... increased the risk for estrogen receptor-negative and progesterone receptor-positive ... for a long time for white women, but now ... author Esther John, a senior research scientist at the ...
(Date:10/31/2014)... CA (PRWEB) October 31, 2014 Gold ... shoppers to find affordable but tasteful gifts for the wine ... Annual Early Bird Gift Giving Special , which Early ... when they purchase Wine Club Gift membership. , Gift ... advantage of this special. Besides offering discounts, Gold Medal Wine ...
(Date:10/31/2014)... 2014 Florida Air Academy, the ... in grades 6-12, is taking the lead when ... and concussions, becoming the first high school in ... Post-Concussion Assessment and Cognitive Testing) computerized assessment to ... lawsuit grabs the headlines, and the Centers for ...
Breaking Medicine News(10 mins):Health News:"Memory Healer" Review Reveals a New Natural Remedy Guide for Managing Memory Loss 2Health News:New School Vision Initiative Announced by Dr. Rosenak’s Optical Options; Program Aims to Help Recognize Unseen Vision Problems That Impact School Success 2Health News:New School Vision Initiative Announced by Dr. Rosenak’s Optical Options; Program Aims to Help Recognize Unseen Vision Problems That Impact School Success 3Health News:Study Confirms Obesity-Breast Cancer Link for Blacks, Hispanics 2Health News:Gold Medal Wine Club now offering Early Bird Gift Giving Special for Holidays 2Health News:Florida Air Academy Tackling Concussions Head-On 2Health News:Florida Air Academy Tackling Concussions Head-On 3
(Date:10/30/2014)... 30, 2014 WuXi PharmaTech (Cayman) Inc. (NYSE: ... technology platform company serving the pharmaceutical, biotechnology, and medical ... and the United States , ... the Tel Aviv area of ... WuXi,s broad platform of integrated R&D services to local ...
(Date:10/30/2014)... Boston Scientific Corporation (NYSE: BSX ... Suisse Annual Healthcare Conference on Tuesday, November 11, 2014 ... Brennan , executive vice president and chief financial officer, ... approximately 8:00 a.m. PT followed by a question and ... presentation and question and answer session will be available ...
(Date:10/30/2014)... , Oct. 30, 2014   ViaDerma, Inc. ... to bringing new products to market, has recently ... TetraStem. TetraStem is a topical liquid tetracycline-based antibiotic ... that can convert oral medication active ingredients into ... a first aid antibiotic to help prevent skin ...
Breaking Medicine Technology:WuXi AppTec Launches Representative Office in Israel, Forms Strategic Collaboration with Pontifax 2Boston Scientific To Participate In 2014 Credit Suisse Annual Healthcare Conference 2ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 2ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 3
Cached News: